These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25163706)

  • 21. Is the recent ban on animal testing of legal high products a fatal blow to the development of a legal market for 'low-risk' psychoactive products in New Zealand?
    Rychert M; Wilkins C
    Addiction; 2015 Apr; 110(4):714-5. PubMed ID: 25771695
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thirty-one psychoactive plants exempted from New Zealand's Psychoactive Substances Act 2013.
    Rychert M; Wilkins C
    Addiction; 2017 Jan; 112(1):181-182. PubMed ID: 27549982
    [No Abstract]   [Full Text] [Related]  

  • 24. Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age.
    Griffiths P; Evans-Brown M; Sedefov R
    Addiction; 2013 Oct; 108(10):1700-3. PubMed ID: 23865891
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of legal bans on poison control center contacts regarding 'legal highs'.
    Loeffler G; Craig C
    Addiction; 2013 Jul; 108(7):1348-9. PubMed ID: 23617711
    [No Abstract]   [Full Text] [Related]  

  • 26. Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective.
    Duffert A
    Drug Test Anal; 2014; 6(7-8):876-8. PubMed ID: 24415657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New psychoactive substances: Can there be any effective legal enforcement?
    Khanra S; Munda SK; Khess CRJ; Maity M
    Asian J Psychiatr; 2017 Dec; 30():165-166. PubMed ID: 29073586
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulatory approaches to new psychoactive substances (NPS) in the European Union.
    Hughes B; Griffiths P
    Addiction; 2014 Oct; 109(10):1591-3. PubMed ID: 25163707
    [No Abstract]   [Full Text] [Related]  

  • 30. Exploring the Attractiveness of New Psychoactive Substances (NPS) among Experienced Drug Users.
    van Amsterdam JG; Nabben T; Keiman D; Haanschoten G; Korf D
    J Psychoactive Drugs; 2015; 47(3):177-81. PubMed ID: 26098724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A critical examination of the definition of 'psychoactive effect' in Australian drug legislation.
    Barratt MJ; Seear K; Lancaster K
    Int J Drug Policy; 2017 Feb; 40():16-25. PubMed ID: 27884504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'Heads held high': an exploratory study of legal highs in pre-legislation Ireland.
    Van Hout MC; Brennan R
    J Ethn Subst Abuse; 2011; 10(3):256-72. PubMed ID: 21888502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing.
    Wilkins C
    Drug Test Anal; 2014; 6(7-8):868-75. PubMed ID: 24817124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Psychoactive Substances (NPS) - the Hydra monster of recreational drugs.
    Helander A; Bäckberg M
    Clin Toxicol (Phila); 2017 Jan; 55(1):1-3. PubMed ID: 27549399
    [No Abstract]   [Full Text] [Related]  

  • 35. New psychoactive substances detected at the New Zealand border, 2014-2018.
    Johnson CS; Copp BR; Lewis A
    Drug Test Anal; 2019 Feb; 11(2):341-346. PubMed ID: 30346116
    [No Abstract]   [Full Text] [Related]  

  • 36. A chorus of pessimism surrounding the new psychoactive substances problem.
    Pardo B; Reuter P
    Addiction; 2017 Jan; 112(1):38-39. PubMed ID: 27753224
    [No Abstract]   [Full Text] [Related]  

  • 37. From concept(ion) to life after death/the grave: The 'natural' history and life cycle(s) of novel psychoactive substances (NPS).
    Corkery JM; Orsolini L; Papanti D; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New psychoactive substances: a public health issue.
    Guirguis A
    Int J Pharm Pract; 2017 Oct; 25(5):323-325. PubMed ID: 28895252
    [No Abstract]   [Full Text] [Related]  

  • 39. Synthetic cannabinoid presentations decline following ban.
    Christie G; MacFarlane V
    Drug Alcohol Rev; 2016 Mar; 35(2):E3-4. PubMed ID: 26492870
    [No Abstract]   [Full Text] [Related]  

  • 40. Legal highs - legal aspects and legislative solutions.
    Kapka-Skrzypczak L; Kulpa P; Sawicki K; Cyranka M; Wojtyła A; Kruszewski M
    Ann Agric Environ Med; 2011; 18(2):304-9. PubMed ID: 22216803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.